FDA Should Call Last Round For OTC Hangover Indication, Cmte. Suggests
This article was originally published in The Pink Sheet
Executive Summary
Comments from the Nonprescription Drug and the Drug Safety and Risk Management advisory committees during a joint meeting could push US FDA toward pulling the plug on hangover as a monograph indication.
You may also be interested in...
US Firm's Supplement Claims For Hangover Relief Watered Down In Industry Self-Regulation Review
More Labs’ online claims might not be distilled satisfactorily for FDA’s taste for dietary supplement claims for hangover help agency made known a year ago. Firm will narrow claim suggesting its products could broadly relieve hangover symptoms.
Widely Available Unapproved Hangover Remedies Concern US FDA As Encouraging Overindulgence
As CFSAN warned seven marketers, supplement products from numerous other businesses advertised as hangover remedies, or as formulations to prevent symptoms associated with overindulgence, remained available to US consumers. Like one business FDA warned, numerous companies are offering OTC intravenous treatments for hangovers, available at locations accepting walk-in or by-appointment customers.
No Regulatory Imprimatur In UK For Scottish Firm’s Hangover Remedy Claim
Bounce Back Drinks sought to establish its bona fides as a registered consumer product provider, but statements referencing ASA, EFSA and MHRA imply the agencies reviewed and approved its product and advertising. Plus, hangover remedy claims are prohibited under UK regulations.